POINT Biopharma Global Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

POINT Biopharma Global wird ein Gewinn- und Umsatzwachstum von 9.2% bzw. 22.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 10.5% pro Jahr wachsen soll.

Wichtige Informationen

9.2%

Wachstumsrate der Gewinne

10.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.2%
Wachstumsrate der Einnahmen	22.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Dec 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PNT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	159	-43	208	110	4
12/31/2024	69	-41	-35	-135	7
12/31/2023	18	-95	-70	-102	8
9/30/2023	244	97	93	112	N/A
6/30/2023	241	97	97	118	N/A
3/31/2023	236	98	156	172	N/A
12/31/2022	227	98	171	184	N/A
9/30/2022	N/A	-79	-78	-65	N/A
6/30/2022	N/A	-72	-65	-56	N/A
3/31/2022	N/A	-56	-54	-44	N/A
12/31/2021	N/A	-46	-54	-45	N/A
9/30/2021	N/A	-37	-48	-38	N/A
6/30/2021	N/A	-23	-37	-24	N/A
3/31/2021	N/A	-18	-29	-19	N/A
12/31/2020	N/A	-13	-18	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PNTDas prognostizierte Gewinnwachstum (9.2% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: PNTDie Erträge des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: PNTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: PNTDie Einnahmen des Unternehmens (22.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: PNTDie Einnahmen des Unternehmens (22.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PNT in 3 Jahren voraussichtlich hoch sein wird

POINT Biopharma Global Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 19% to US$13.85

Consensus revenue estimates increase by 24%

Price target decreased by 9.2% to US$15.44

Consensus revenue estimates fall by 54%

Consensus EPS estimates upgraded to US$0.80 loss

Price target increased by 7.3% to US$16.90

Recent updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 24%

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

New major risk - Share price stability

Price target decreased by 9.2% to US$15.44

Investor sentiment improves as stock rises 81%

Consensus revenue estimates fall by 54%

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

High number of new directors

POINT Biopharma Global Inc. Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Consensus EPS estimates upgraded to US$0.80 loss

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

Price target increased by 7.3% to US$16.90

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 18%

Independent Director exercised options to buy US$122k worth of stock.

Forecast to breakeven in 2024

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial

POINT Biopharma Global Inc. Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Executive Chairman recently bought US$311k worth of stock

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to US$19.00

High number of new directors

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, A Next-Generation PSMA Ligand, At EANM's Annual Congress

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Price target increased to US$21.00

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Chief Medical Officer & Director recently sold US$4.2m worth of stock

POINT Biopharma Global Inc. Unveils FRONTIER: A Pan-Cancer Fap-A Targeted Clinical Program

POINT Biopharma Global Inc. Confirms No Supply Shortages of 177Lu-PNT2002 for the Splash Trial

High number of new and inexperienced directors

POINT Biopharma Global Announces First Patient in European Union (EU) Dosed in the Phase 3 Splash Trial

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH Trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

POINT Biopharma Global Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

POINT Biopharma Global Inc. Releases New Data and Exercises Option for Best-In-Class FAP Inhibitor

POINT Biopharma Global Inc. Announces Initiation of Randomization for Its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of Its Phase 3 SPLASH Study of PNT2002 for mCRPC

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken